Related Experiment Video
Updated: Jun 16, 2026
05:29
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
3.1K
Glofitamab combined with tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: a single-center pilot
De Zhou1,2,3,4, Wenjuan Yu1,2,3,4, Mixue Xie1,2,3,4
1Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Blood Cancer Journal
|November 2, 2025
Abstract
No abstract available in PubMed .
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...